Clinical Trial Update: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies [Phase 2]

View source ↗

Summary

A Phase II clinical trial investigating adjuvant immunotherapy targeting KRAS G12D, KRAS G12V, and TP53 R175H across several gastrointestinal cancers has been w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Duodenal Cancer
• Hepatocellular Carcinoma
• Pancreatic Cancer
• Small Intestine Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Status: WITHDRAWN